Table 4.
Survival compared to literature on prospective clinical trials and retrospective observational studies.
| Setting | Current study | Clinical Trial Setting | Observational |
|---|---|---|---|
| Median OS [95%CI] | Median OS | Median OS | |
| MIBC or locally advanced disease | |||
| RC alone | 47.4 months [28.9–65.8] | 46 months1 | 54 months19 |
| NAC + RC | 35.3 months [5.6–64.9]* | 77 months1 | 68 months19 |
| IC + RC | 19.5 months [0.0–49.1] | – | 18–26 months20 |
| Best Supportive Care | 3.8 months [3.2–4.4] | – | 5.3 months17 |
| Metastatic or inoperable disease | |||
| First-line chemotherapy (1L) | 12.6 months [8.8–16.4] | 14.0–15.2 months4 | 16.1 months24 |
| 12.7–15.8 months5 | |||
| Recurrent disease after RC | 7.5 months [0.0–15.6] | 5.2 months25 | - |
| Second-line chemotherapy (2L) | 6.6 months [4.7–8.4] | 5.9–7.0 months7,8 | 9.2 months24 |
| Best Supportive Care (BSC) | 2.0 months [0.9–3.2] | 4.3–4.6 months5,7 | - |
MIBC muscle-invasive bladder cancer, RC radical cystectomy, NAC neoadjuvant chemotherapy, IC induction chemotherapy, 95% CI 95% confidence interval.
*Patients with cT2N0M0 are not treated with NAC before RC in our hospital, and thus not present in this group.